A constitutive active MAPK/ERK pathway due to BRAF V600E  positively regulates AHR pathway in PTC

Gianluca Occhi; Susi Barollo; Daniela Regazzo; Loris Bertazza; Francesca Galuppini; Vincenza Guzzardo; Marie Lise Jaffrain-Rea; Federica Vianello; Denis Ciato; Filippo Ceccato; Sara Watutantrige-Fernando; Andrea Bisognin; Stefania Bortoluzzi; Gianmaria Pennelli; Marco Boscaro; Carla Scaroni; Caterina Mian

doi:10.18632/oncotarget.5194

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

A constitutive active MAPK/ERK pathway due to BRAF^V600E positively regulates AHR pathway in PTC

Gianluca Occhi _, Susi Barollo, Daniela Regazzo, Loris Bertazza, Francesca Galuppini, Vincenza Guzzardo, Marie Lise Jaffrain-Rea, Federica Vianello, Denis Ciato, Filippo Ceccato, Sara Watutantrige-Fernando, Andrea Bisognin, Stefania Bortoluzzi, Gianmaria Pennelli, Marco Boscaro, Carla Scaroni and Caterina Mian

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:32104-32114. https://doi.org/10.18632/oncotarget.5194

Metrics: PDF 1887 views | HTML 2154 views | ?

Abstract

Gianluca Occhi1,*, Susi Barollo2,*, Daniela Regazzo2, Loris Bertazza2, Francesca Galuppini3, Vincenza Guzzardo3, Marie Lise Jaffrain-Rea4,5, Federica Vianello6, Denis Ciato2, Filippo Ceccato2, Sara Watutantrige-Fernando2, Andrea Bisognin1, Stefania Bortoluzzi7, Gianmaria Pennelli3, Marco Boscaro2, Carla Scaroni2, Caterina Mian2

1Department of Biology, University of Padova, Padova, Italy

2Endocrinology Division, Department of Medicine, Hospital/University of Padova, Padova, Italy

3Surgical Pathology & Cytopathology Unit, Department of Medicine, Hospital/University of Padova, Padova, Italy

4Department of Clinical and Biotechnological Sciences, University of L’Aquila, L’Aquila, Italy

5Neuromed Institute, Department of Neurological Sciences, University of L’Aquila, L’Aquila, Italy

6Department of Radiotherapy, Istituto Oncologico del Veneto, IOV-IRCCS, Padova, Italy

7Department of Molecular Medicine, University of Padova, Padova, Italy

*These authors have contributed equally to this work

Correspondence to:

Gianluca Occhi, e-mail: [email protected]

Keywords: papillary thyroid cancer, aryl hydrocarbon receptor, BRAF, gene expression, meta-analysis

Received: April 30, 2015 Accepted: September 03, 2015 Published: September 16, 2015

ABSTRACT

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor mediating the toxicity and tumor-promoting properties of dioxin. AHR has been reported to be overexpressed and constitutively active in a variety of solid tumors, but few data are currently available concerning its role in thyroid cancer. In this study we quantitatively explored a series of 51 paired-normal and papillary thyroid carcinoma (PTC) tissues for AHR-related genes. We identified an increased AHR expression/activity in PTC, independently from its nuclear dimerization partner and repressor but strictly related to a constitutive active MAPK/ERK pathway. The AHR up-regulation followed by an increased expression of AHR target genes was confirmed by a meta-analysis of published microarray data, suggesting a ligand-independent active AHR pathway in PTC. In-vitro studies using a PTC-derived cell line (BCPAP) and HEK293 cells showed that BRAF^V600E may directly modulate AHR localization, induce AHR expression and activity in an exogenous ligand-independent manner. The AHR pathway might represent a potential novel therapeutic target for PTC in the clinical practice.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5194

Publication Alerts

Research Papers:

A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC

Abstract

A constitutive active MAPK/ERK pathway due to BRAF^V600E positively regulates AHR pathway in PTC